

# Sequencing of therapy following first-line afatinib in pa non-small cell lung cancer

Lung Cancer

132, 126-131

DOI: [10.1016/j.lungcan.2019.04.014](https://doi.org/10.1016/j.lungcan.2019.04.014)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. <i>Future Oncology</i> , 2019, 15, 2905-2914.	1.1	71
2	Dynamics of Circulating Tumor Cells Early After Targeting Therapy to Human <i>EGFR</i> -mutated Lung Cancers and <i>HER2</i> Gene-amplified Gastric Cancers in Mice. <i>Anticancer Research</i> , 2019, 39, 4711-4720.	0.5	5
3	Optimizing outcomes and treatment sequences in <i>EGFR</i> mutation-positive non-small-cell lung cancer: recent updates. <i>Future Oncology</i> , 2019, 15, 2983-2997.	1.1	27
4	Therapies after first-line afatinib in patients with <i>EGFR</i> <sup>+</sup> NSCLC in Japan: retrospective analysis of LUX-Lung 3. <i>Future Oncology</i> , 2020, 16, 49-60.	1.1	4
5	Tyrosine Kinase Inhibitors for the Treatment of <i>EGFR</i> Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations. <i>Clinical Lung Cancer</i> , 2020, 21, e216-e228.	1.1	89
6	Osimertinib versus platinum-pemetrexed for patients with <i>EGFR</i> T790M advanced NSCLC and progression on a prior <i>EGFR</i> -tyrosine kinase inhibitor: AURA3 overall survival analysis. <i>Annals of Oncology</i> , 2020, 31, 1536-1544.	0.6	149
7	Afatinib for the first-line treatment of <i>EGFR</i> mutation-positive NSCLC in China: a review of clinical data. <i>Future Oncology</i> , 2020, 16, 2569-2586.	1.1	2
8	Making the case for <i>EGFR</i> TKI sequencing in <i>EGFR</i> mutation-positive NSCLC: a GioTag study US patient analysis. <i>Future Oncology</i> , 2020, 16, 1585-1595.	1.1	5
9	Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. <i>Future Oncology</i> , 2020, 16, 2799-2808.	1.1	50
10	Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment. <i>Cancers</i> , 2020, 12, 1587.	1.7	24
11	Impact of the generation of <i>EGFR</i> TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring <i>EGFR</i> T790M mutation. <i>Thoracic Cancer</i> , 2021, 12, 329-338.	0.8	2
12	Acquired resistance to third-generation <i>EGFR</i> -TKIs and emerging next-generation <i>EGFR</i> inhibitors. <i>Innovation(China)</i> , 2021, 2, 100103.	5.2	47
13	A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for <i>EGFR</i> -mutated non-small-cell lung cancer from practical dataset: CJLSG1903. <i>ESMO Open</i> , 2021, 6, 100115.	2.0	30
14	Survival of Patients with Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer Treated beyond the Second Line in the Tyrosine Kinase Inhibitor Era. <i>Cancers</i> , 2021, 13, 3887.	1.7	2
15	Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG). <i>Lung Cancer</i> , 2021, 162, 9-15.	0.9	18
16	Improvement of Overall Survival Using TKIs as Salvage Therapy in Advanced Thyroid Carcinoma: Real-Life Data on a Single Center Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 384.	1.0	4
17	Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring <i>EGFR</i> mutations. <i>Translational Lung Cancer Research</i> , 2021, 10, 183-192.	1.3	7
18	Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in <i>EGFR</i> -mutated non-small-cell lung cancer: a real life study. <i>Future Oncology</i> , 2020, 16, 1115-1124.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Critical Review of EGFR-Mutated NSCLC: What We Do and Do Not Know. Healthbook TIMES Oncology Hematology, 2020, , 20-35.	0.1	3
20	Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer. Egyptian Journal of Bronchology, 2022, 16, .	0.3	0
21	Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer, 2022, 170, 41-51.	0.9	33
22	Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22. Translational Lung Cancer Research, 2022, 11, 1369-1379.	1.3	9
23	Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211032.	0.6	2
24	Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting. Thoracic Cancer, 2022, 13, 2057-2063.	0.8	4
25	Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies. OncoTargets and Therapy, 0, Volume 15, 873-882.	1.0	6